Argenx SE is discussing its research and development efforts, focusing on advancing FcRn leadership in autoimmune myositis. The company is hosting a webinar on its R&D, with reported dates varying. The webinar is expected to highlight the company's work on autoimmune myositis, possibly including a focus on ARGX-119.